Medtronic plc (MDT) Insider Transactions
Over the last 12 months, 21 Medtronic plc (MDT) insiders filed 104 SEC Form 4 transactions: $0 in open-market purchases ( 0 distinct buyers) and $8.9M in open-market sales. 0% of all transactions were executed under a pre-scheduled Rule 10b5-1 trading plan.
- $0Open-market buys (1y)
- $8.9MOpen-market sells (1y)
- 21Distinct insiders
- 104Transactions filed
- 0%Under Rule 10b5-1 plan
- 2026-09-16Latest filing
Recent Form 4 Filings Most recent 50 of 104 (1-year window)
Each row is a single Form 4 filing event for MDT, sourced directly from SEC EDGAR. The Type column classifies the SEC transaction code into Buy / Sell / Grant / Exercise / Other; the 10b5-1 badge marks trades executed under a pre-scheduled SEC Rule 10b5-1 plan.
| Date | Insider | Title | Type | SEC Code | Value | Shares | Price |
|---|---|---|---|---|---|---|---|
| 2026-09-16 | KIIL HARRY SKIP | EVP & President Cardiovascular | Sell | S | $138.9K | 1,483 | $93.7 |
| 2026-09-15 | Blomquist Denise L. | Chief Accounting Officer | Other | G | $0 | 600 | $0.0 |
| 2026-08-20 | Marinaro Michael | EVP, Pres MedSurg and Americas | Other | F | $100.1K | 1,084 | $92.3 |
| 2026-08-03 | Blomquist Denise L. | Chief Accounting Officer | Grant | A | $0 | 2,337 | $0.0 |
| 2026-08-03 | Blomquist Denise L. | Chief Accounting Officer | Grant | A | $0 | 2,337 | $0.0 |
| 2026-08-03 | Blomquist Denise L. | Chief Accounting Officer | Grant | A | $0 | 1,366 | $0.0 |
| 2026-08-03 | Walter Matthew R. | SVP, Chief HR Officer | Grant | A | $0 | 5,769 | $0.0 |
| 2026-08-03 | Walter Matthew R. | SVP, Chief HR Officer | Grant | A | $0 | 14,421 | $0.0 |
| 2026-08-03 | Walter Matthew R. | SVP, Chief HR Officer | Grant | A | $0 | 40,973 | $0.0 |
| 2026-08-03 | Thompson Kweli | EVP & President, Neuroscience | Grant | A | $0 | 6,923 | $0.0 |
| 2026-08-03 | Thompson Kweli | EVP & President, Neuroscience | Grant | A | $0 | 17,306 | $0.0 |
| 2026-08-03 | Thompson Kweli | EVP & President, Neuroscience | Grant | A | $0 | 49,167 | $0.0 |
| 2026-08-03 | Quinn Michelle | EVP, GC and Secretary | Grant | A | $0 | 6,346 | $0.0 |
| 2026-08-03 | Quinn Michelle | EVP, GC and Secretary | Grant | A | $0 | 15,863 | $0.0 |
| 2026-08-03 | Quinn Michelle | EVP, GC and Secretary | Grant | A | $0 | 45,070 | $0.0 |
| 2026-08-03 | Pieton Thierry | EVP & Chief Financial Officer | Grant | A | $0 | 11,537 | $0.0 |
| 2026-08-03 | Pieton Thierry | EVP & Chief Financial Officer | Grant | A | $0 | 28,842 | $0.0 |
| 2026-08-03 | Pieton Thierry | EVP & Chief Financial Officer | Grant | A | $0 | 81,945 | $0.0 |
| 2026-08-03 | Marinaro Michael | EVP, Pres MedSurg and Americas | Grant | A | $0 | 10,960 | $0.0 |
| 2026-08-03 | Marinaro Michael | EVP, Pres MedSurg and Americas | Grant | A | $0 | 46,147 | $0.0 |
| 2026-08-03 | Marinaro Michael | EVP, Pres MedSurg and Americas | Grant | A | $0 | 27,400 | $0.0 |
| 2026-08-03 | Marinaro Michael | EVP, Pres MedSurg and Americas | Grant | A | $0 | 77,848 | $0.0 |
| 2026-08-03 | KIIL HARRY SKIP | EVP & President Cardiovascular | Grant | A | $0 | 9,230 | $0.0 |
| 2026-08-03 | KIIL HARRY SKIP | EVP & President Cardiovascular | Grant | A | $0 | 23,074 | $0.0 |
| 2026-08-03 | KIIL HARRY SKIP | EVP & President Cardiovascular | Grant | A | $0 | 65,556 | $0.0 |
| 2026-08-03 | Martha Geoffrey | Chairman and CEO | Grant | A | $0 | 41,533 | $0.0 |
| 2026-08-03 | Martha Geoffrey | Chairman and CEO | Grant | A | $0 | 103,831 | $0.0 |
| 2026-08-03 | Martha Geoffrey | Chairman and CEO | Grant | A | $0 | 295,002 | $0.0 |
| 2026-08-03 | Martha Geoffrey | Chairman and CEO | Grant | A | $0 | 273,150 | $0.0 |
| 2026-07-31 | Blomquist Denise L. | Chief Accounting Officer | Other | F | $18.1K | 212 | $85.4 |
| 2026-07-31 | Walter Matthew R. | SVP, Chief HR Officer | Other | F | $143.0K | 1,675 | $85.4 |
| 2026-07-31 | Thompson Kweli | EVP & President, Neuroscience | Other | F | $148.5K | 1,739 | $85.4 |
| 2026-07-31 | Marinaro Michael | EVP, Pres MedSurg and Americas | Other | F | $286.6K | 3,356 | $85.4 |
| 2026-07-31 | KIIL HARRY SKIP | EVP & President Cardiovascular | Other | F | $262.5K | 3,074 | $85.4 |
| 2026-07-31 | Martha Geoffrey | Chairman and CEO | Other | F | $1.4M | 15,810 | $85.4 |
| 2026-07-28 | Quinn Michelle | EVP, GC and Secretary | Other | F | $179.8K | 2,069 | $86.9 |
| 2026-07-08 | Walter Matthew R. | SVP, Chief HR Officer | Sell | S | $257.9K | 3,102 | $83.2 |
| 2026-06-08 | KIIL HARRY SKIP | EVP & President Cardiovascular | Sell | S | $318.6K | 3,961 | $80.4 |
| 2026-06-08 | KIIL HARRY SKIP | EVP & President Cardiovascular | Sell | S | $18.3K | 228 | $80.5 |
| 2026-06-05 | Blomquist Denise L. | Chief Accounting Officer | Other | F | $19.7K | 237 | $83.3 |
| 2026-06-04 | KIIL HARRY SKIP | EVP & President Cardiovascular | Other | F | $568.0K | 6,817 | $83.3 |
| 2026-06-04 | Martha Geoffrey | Chairman and CEO | Other | F | $3.5M | 41,936 | $83.3 |
| 2026-06-04 | Marinaro Michael | EVP, Pres MedSurg and Americas | Other | F | $622.5K | 7,471 | $83.3 |
| 2026-06-04 | Walter Matthew R. | SVP, Chief HR Officer | Other | F | $236.6K | 2,840 | $83.3 |
| 2026-05-26 | Walter Matthew R. | SVP, Chief HR Officer | Exercise | M | $0 | 9,149 | $0.0 |
| 2026-05-26 | Walter Matthew R. | SVP, Chief HR Officer | Exercise | M | $0 | 8,449 | $0.0 |
| 2026-05-26 | Wall Brett A. | EVP & Pres Neuroscience | Exercise | M | $0 | 26,907 | $0.0 |
| 2026-05-26 | Wall Brett A. | EVP & Pres Neuroscience | Exercise | M | $0 | 24,214 | $0.0 |
| 2026-05-26 | Martha Geoffrey | Chairman and CEO | Exercise | M | $0 | 94,963 | $0.0 |
| 2026-05-26 | Martha Geoffrey | Chairman and CEO | Exercise | M | $0 | 85,461 | $0.0 |
Showing the most recent 50 of 104 transactions. For the full 1-year history with sorting, filtering, and cross-ticker industry context, open the full insider transactions drilldown.
Methodology & FAQ
How We Track MDT Insider Transactions
Form 4 disclosures are sourced directly from SEC EDGAR and re-ingested on every pipeline cycle. A complete description of transaction-code handling, the open-market vs grant distinction, and the Rule 10b5-1 plan-reference heuristic is documented in the Methodology.
What is an SEC Form 4 filing for Medtronic plc?
Form 4 is a transaction-level disclosure that corporate insiders (officers, directors, and beneficial owners of more than 10% of a registered class of equity securities) must file with the SEC within two business days of any change in their beneficial ownership of Medtronic plc (MDT) shares.
What is a Rule 10b5-1 trading plan?
Rule 10b5-1 is an SEC rule that lets insiders schedule trades in advance under a written plan, providing an affirmative defense against insider-trading allegations as long as the plan was adopted in good faith and not while in possession of material non-public information. Form 4 rows marked "10b5-1" on this page indicate the underlying trade was executed under such a plan; rows without the badge are discretionary or did not reference a plan in the Form 4 footnotes.
How is "insider buying" different from a stock grant or option exercise?
An insider buy (SEC transaction code P) is an open-market purchase of Medtronic plc (MDT) stock executed at the prevailing market price using the insider's personal capital. Stock grants (code A) and option exercises (code M) are compensation events, not directional trades; they are tracked separately and excluded from the "conviction" signal because they are not discretionary purchases.
How recent is the data?
Form 4 transactions are typically reported within two business days of execution. Pactolio re-ingests the EDGAR feed on a nightly cycle and reflects new filings on the next ingest run, typically within 24 hours of EDGAR acceptance. The table on this page covers the most recent 1-year window.